Mark McDade co-founded Qiming US in January 2017 and has over 30 years of successful operating experience in private and public healthcare and life science companies. Prior to Qiming US, Mark was Executive Vice President and Chief Operating Officer (COO) at UCB, the Brussels, Belgium-based global biopharma company.
Previously, Mark served as Chief Executive Officer (CEO) and a director of PDL Biopharma and led Signature Bioscience as its CEO. Mark was also a founder and director of Corixa Corporation, where he served as COO and then President and COO. Earlier in his career, Mark was COO of Boehringer Mannheim Therapeutics. Prior to that, he held several positions of increasing responsibility at Sandoz Ltd. (now part of Novartis), including business development, product management and general management.